Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab in patients with Follicular Lymphoma.
This statement is based on a regulatory approval from the Health Service Executive:
In combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma.